A real long term stock, Copied from the link: Before this trial...

A real long term stock,
Copied from the link:

Before this trial can commence the Progenza technology will need to be transferred to AGC, which will undertake GMP manufacture of Progenza for the trial. We assume that the technology transfer and validation of Progenza manufacture by AGC would be completed in H1 CY19, enabling a Phase II trial in Japan to commence in Q3 CY19 and report results in Q1 CY21, allowing a potential market launch in early 2022.